摘要
血液肿瘤复发仍是异基因造血干细胞移植(allo-HSCT)主要死亡原因之一,allo-HSCT后复发的预测、防治等问题的解决是提高疗效、改善预后的关键。文章结合第60届美国血液学会年会的代表性报道,总结了allo-HSCT后的复发预测、防治及预后评估的相关研究进展。
Hematologic neoplasm relapse remains one of the major causes of death after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Relaspe prediction,prophylaxis and treatment after allo-HSCT are the key issues for improving the therapeutic effects and prognosis.This paper chooses some representative reports from 60th American Society of Hematology(ASH)Annual Meeting to discuss the progress of allo-HSCT.
作者
李思琦
常英军
Li Siqi;Chang Yingjun(Peking University People's Hospital & Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China)
出处
《白血病．淋巴瘤》
CAS
2019年第1期17-20,共4页
Journal of Leukemia & Lymphoma
关键词
血液肿瘤
造血干细胞移植
复发
嵌合抗原受体T细胞
适应证
Hematologic neoplasms
Hematopoietic stem cell transplantation
Recurrence
Chimeric antigen receptor T-cell
Indication
